Contrasting Prothena (NASDAQ:PRTA) & Relay Therapeutics (NASDAQ:RLAY)

Prothena (NASDAQ:PRTA – Get Free Report) and Relay Therapeutics (NASDAQ:RLAY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Profitability

This table compares Prothena and Relay Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Prothena -45.44% -9.98% -9.08%
Relay Therapeutics N/A -40.25% -36.82%

Analyst Ratings

This is a summary of recent ratings for Prothena and Relay Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prothena 1 1 3 2 2.86
Relay Therapeutics 1 1 11 1 2.86

Prothena currently has a consensus target price of $20.00, suggesting a potential upside of 150.94%. Relay Therapeutics has a consensus target price of $27.00, suggesting a potential upside of 56.34%. Given Prothena’s higher possible upside, equities research analysts clearly believe Prothena is more favorable than Relay Therapeutics.

Institutional and Insider Ownership

97.1% of Prothena shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 10.4% of Prothena shares are held by company insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Prothena and Relay Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Prothena $9.68 million 42.28 -$244.09 million ($0.48) -16.60
Relay Therapeutics $15.35 million 248.60 -$276.48 million ($1.51) -11.44

Prothena has higher earnings, but lower revenue than Relay Therapeutics. Prothena is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Prothena has a beta of -0.2, meaning that its stock price is 120% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.74, meaning that its stock price is 74% more volatile than the S&P 500.

Summary

Prothena beats Relay Therapeutics on 8 of the 14 factors compared between the two stocks.

About Prothena

(Get Free Report)

Prothena Corporation plc is a clinical-stage biotechnology company developing treatments for diseases associated with protein misfolding and dysfunction. Its research focuses on using antibodies and other biologic approaches to target proteins implicated in neurological and systemic disorders. The company’s pipeline has included programs for Parkinson’s disease, Alzheimer’s disease and AL amyloidosis. Its investigational therapies include prasinezumab, developed in collaboration with Roche, and programs targeting amyloid beta and transthyretin-related disease.

About Relay Therapeutics

(Get Free Report)

Relay Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing medicines for patients with serious diseases, with an emphasis on cancer. The company uses its computational drug discovery platform to study how proteins move and interact, aiming to identify drug targets and design therapies against them. Relay’s research combines experimental biology, structural biology and computational methods. Its drug development programs have included candidates targeting cancer-related pathways, such as FGFR2 and PI3Kα.

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.